- US Recovery to be Weak, Erratic: Top Fed Officials
- AIG CEO Ready to Quit over Pay Constraints: Report
- Retail Earnings in Focus Ahead of Shopping Season
- Apple Surpasses Nokia as Top Handset Maker by Profit
- Brazil's Largest Cities Hit by Blackout
- In This Relay-Race Market, Who Gets Baton Next?
- Workers Staying Put at Their Jobs as Jobless Surges
- Ponzi Proceeds: Bidding on Madoff's Toys
- Toll Brothers: More Contracts Signed, but Sales Down
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
MOST SHARED
- Herbalife Vs. Hedge Funds
- AIG CEO Ready to Quit over Pay Constraints: Report
- Apple Surpasses Nokia as Top Cellphone Maker by Profits
- China Factory Output Leaps to 19-Month Highs
- America Is On Sale
- Toll Brothers: More Contracts Signed, but Sales Down
- Cramer Jeers J&J, Applauds Abbott
- Three Things the US Can Do To Stop the Dollar's Decline
Text Size 
A cancer drug may help people hear better.
That's the unusual finding of a very small study being published in the prestigious "New England Journal of Medicine."
Harvard researchers tested Roche and Genentech's Avastin on patients who have a rare, genetic and potentially fatal condition that causes noncancerous tumors to form around a nerve in the brain that connects to the inner ear. As a result, many patients lose their hearing at an early age.
But when seven people with neurofibromatosis-Type 2 were given the intravenous Avastin infusion every two weeks for about a year, some of the tumors shrank and, as a result, a handful of the patients saw dramatic improvements in their hearing.
 |
Two of them regained "useful hearing" and were able to go back to work or school. And two others were able to read lips or converse better. Three of the patients, for various reasons, did not hear better.
Neurofibromatosis-Type 2 occurs in an estimated one in 50,000 to 120,000 births.
Genentech did not pay for the study.
Print
Email
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- If you are lucky enough to have money and the time, this is a great time to see America, says CNBC's Jane Wells.
- What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
- One author sees lessons for you in Disney’s recent Makeover of Mickey Mouse: “Nice” doesn’t always win.
- With 123 years of history, slogans and commercials, Coca-Cola is the most recognized brand on earth.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
Data is a real-time snapshot *Data is delayed at least 15 minutes